AAAnass Abbad

Anass Abbad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anass Abbad has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mosaic-hemagglutinin-based influenza B mRNA-LNP vaccine induces strong humoral immune response in non-human primates

    by Máté Vadovics, Anass Abbad, Temima Yellin, Juan Manuel Carreño, Kieu Lam, Hiromi Muramatsu, Emily F. Daley, András Sárközy, Weina Sun, James Heyes, et al.

  • Top Cited Papers
    Open Access

    Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination

    by Anass Abbad, Brian Lerman, Jordan Ehrenhaus, Brian Monahan, Gagandeep Singh, Adria Wilson, Stefan Slamanig, Ashley Aracena, Neko Lyttle, Jessica R. Nardulli, et al.

    The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by emerging SARS-CoV-2 subvariants. We assessed neutralizing antibody responses in 56 adults with varied exposure histories following KP.2 vaccination against emerging variants including LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2. While KP.2 vaccination enhanced neutralization against homologous variants, substantial reductions in neutralizing activity were observed against emerging Omicron variants across all exposure groups. Exposure history showed some influence on neutralization breadth, with self-reported vaccination-only participants exhibiting better cross-neutralization compared to individuals with hybrid immunity. Antigenic cartography revealed substantial antigenic distances between KP.2 and emerging variants, highlighting significant immune escape potential that threatens vaccine protection. IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, producing variants that escape vaccine-induced immunity. The current work shows that KP.2 monovalent vaccination provides limited protection against antigenically distant Omicron variants (LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2). These findings highlight the ongoing challenge of maintaining vaccine effectiveness against evolving SARS-CoV-2 variants and argue for continuous updating of vaccines.


  • Open Access

    XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies

    by Juan Manuel Carreño, Brian Lerman, Gagandeep Singh, Anass Abbad, Temima Yellin, Jordan Ehrenhaus, Miriam Fried, Jessica R. Nardulli, Hyun Min Kang, Lubbertus C. F. Mulder, et al.

    The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures. First-generation coronavirus disease 2019 (COVID-19) vaccines encoded an ancestral spike protein. Updated bivalent vaccines and breakthrough infections have shaped the intricate diversity of the polyclonal antibody response and specificity of individual antibody clones. We and others previously showed that bivalent vaccines containing the ancestral and Omicron (BA.5) spikes induce high levels of cross-reactive antibodies but undetectable BA.5-specific antibodies in serum. Here, we assessed sera collected before as well as 1 and 3 months following administration of an updated XBB.1.5 monovalent vaccine to individuals with diverse infection and vaccination histories. Vaccination increased neutralization against recent variants of concern, including HV.1, JN.1, and the vaccine-homologous XBB.1.5. Antibody binding and avidity against ancestral and XBB.1.5 antigens significantly increased after vaccination. However, antibody depletion experiments showed that most of the response was cross-reactive to the ancestral spike, and only low levels of XBB.1.5-specific antibodies to the spike or the receptor-binding domain were detected. Importantly, increased antibody levels were still detectable in circulation 3 months post-vaccination and cross-reacted with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) as measured by pseudovirus neutralization and binding assays. Overall, our data suggest that the XBB.1.5 monovalent vaccine predominantly elicits a cross-reactive response imprinted by viral spike antigens encountered early during the pandemic. IMPORTANCE: Updated COVID-19 vaccine formulations and SARS-CoV-2 exposure history affect the antibody response to SARS-CoV-2. High titers of antibodies are induced in serum by XBB.1.5 monovalent vaccination. Antibody depletion experiments reveal that the majority of the antibody response is cross-reactive to the ancestral spike, despite vaccination increasing neutralization against recently circulating Omicron variants. Vaccine-induced SARS-CoV-2 antibodies cross-react with SARS-CoV-1 and remain in the bloodstream for at least 3 months after immunization.


  • Open Access

    Functional and structural analysis of missense variants in the human PDCD1 Gene

    by Hanâ Baba, Meryem Bouqdayr, Anass Abbad, Asmae Saih, Benson R. Kidenya, Mohamed A. Sesay, Simpson Addo, Lahcen Wakrim, Anass Kettani

    Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that regulates T-cell function by modulating and terminating immune responses. Aim: This study investigates the functional and structural impact of missense single nucleotide polymorphisms in the human Programmed Cell Death 1 (PDCD1) gene. Setting: The data related to PDCD1 gene single nucleotide polymorphisms [SNPs] were collected from dbSNP. Methods: PredictSNP1.0, integrating eight tools (sorting intolerant from tolerant [SIFT], PolyPhen-1/2, multivariate analysis of protein polymorphism [MAPP], predictor of human deleterious [PhD] SNP, screening for non-acceptable polymorphisms [SNAP], PANTHER, nsSNPAnalyzer), was used for variant predictions. Conservation was assessed with ConSurf, stability with MUPro and I-Mutant 2.0 and pathogenicity with MutPred2. Molecular dynamics (MD) simulations analysed native and mutant PD-1 variants over 100 nanosecond (ns), assessing root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA) and hydrogen bonding. Results: D117V and W286G were identified as the most deleterious variants. However, W286G was located in an unfavourable structural region, rendering its model unreliable and excluding it from further analysis. Molecular dynamic simulations on the native and D117V models showed no significant differences in RMSD, RMSF, Rg, SASA or hydrogen bonding, suggesting D117V (rs772130993) has minimal impact on PD-1 stability or flexibility. Conclusion: Bioinformatics tools predicted the D117V variant as deleterious, but molecular dynamics simulations suggest it may have limited functional impact. Contribution: These findings underscore the importance of integrating computational predictions with experimental validation to guide therapeutic exploration of genetic variants.

  • Computational analysis of structural and functional evaluation of the deleterious missense variants in the human CTLA4 gene

    by Meryem Bouqdayr, Anass Abbad, Hanâ Baba, Asmae Saih, Lahcen Wakrim, Anass Kettani

    CTLA-4 is an immune checkpoint receptor that negatively regulates the T-cell function expressed after T-cell activation to break the immune response. The current study predicted the genomic analysis to explore the functional variations of missense SNPs in the human CTLA4 gene using PolyPhen2, SIFT, PANTHER, PROVEAN, Fathmm, Mutation Assessor, PhD-SNP, SNPs&GO, SNAP2, and MutPred2. Phylogenetic conservation protein was predicted by ConSurf. Protein structural analysis was carried out by I-Mutant3, MUpro, iStable2, PremPS, and ERIS servers. Molecular dynamics trajectory analysis (RMSD, RMSF, Rg, SASA, H-bonds, and PCA) was performed to analyze the dynamic behavior of native and mutant CTLA-4 at the atomic level. Our in-silico analysis suggested that C58S, G118R, P137Q, P137R, P137L, P138T, and G146L variants were predicted to be the most deleterious missense variants and highly conserved residues. Moreover, the molecular dynamics analysis proposed a decrease in the protein stability and compactness with the P137R and P138T highlighting the impact of these variants on the function of the CTLA-4 protein. Communicated by Ramaswamy H. Sarma


  • Open Access

    Effect of identified non-synonymous mutations in DPP4 receptor binding residues among highly exposed human population in Morocco to MERS-CoV through computational approach

    by Anass Abbad, Latifa Anga, Abdellah Faouzi, Nadia Iounes, Jalal Nourlil

    Dipeptidyl peptidase 4 (DPP4) has been identified as the main receptor of MERS-CoV facilitating its cellular entry and enhancing its viral replication upon the emergence of this novel coronavirus. DPP4 receptor is highly conserved among many species, but the genetic variability among direct binding residues to MERS-CoV restrained its cellular tropism to humans, camels and bats. The occurrence of natural polymorphisms in human DPP4 binding residues is not well characterized. Therefore, we aimed to assess the presence of potential mutations in DPP4 receptor binding domain (RBD) among a population highly exposed to MERS-CoV in Morocco and predict their effect on DPP4 –MERS-CoV binding affinity through a computational approach. DPP4 synonymous and non-synonymous mutations were identified by sanger sequencing, and their effect were modelled by mutation prediction tools, docking and molecular dynamics (MD) simulation to evaluate structural changes in human DPP4 protein bound to MERS-CoV S1 RBD protein. We identified eight mutations, two synonymous mutations (A291 =, R317 =) and six non-synonymous mutations (N229I, K267E, K267N, T288P, L294V, I295L). Through docking and MD simulation techniques, the chimeric DPP4 –MERS-CoV S1 RBD protein complex models carrying one of the identified non-synonymous mutations sustained a stable binding affinity for the complex that might lead to a robust cellular attachment of MERS-CoV except for the DPP4 N229I mutation. The latter is notable for a loss of binding affinity of DPP4 with MERS-CoV S1 RBD that might affect negatively on cellular entry of the virus. It is important to confirm our molecular modelling prediction with in-vitro studies to acquire a broader overview of the effect of these identified mutations.


  • Open Access

    Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018

    by Anass Abbad, Ranawaka Apm Perera, Latifa Anga, Abdellah Faouzi, Nhu Nguyen Tran Minh, Sk Md Mamunur Rahman Malik, Nadia Iounes, Abderrahmane Maaroufi, Maria D Van Kerkhove, Malik Peiris, et al.

    Background: Middle East respiratory syndrome coronavirus (MERS-CoV) remains a major concern for global public health. Dromedaries are the source of human zoonotic infection. MERS-CoV is enzootic among dromedaries on the Arabian Peninsula, the Middle East and in Africa. Over 70% of infected dromedaries are found in Africa. However, all known zoonotic cases of MERS have occurred in the Arabian Peninsula with none being reported in Africa. Aim: We aimed to investigate serological evidence of MERS-CoV infection in humans living in camel-herding areas in Morocco to provide insights on whether zoonotic transmission is taking place. Methods: We carried out a cross sectional seroprevalence study from November 2017 through January 2018. We adapted a generic World Health Organization MERS-CoV questionnaire and protocol to assess demographic and risk factors of infection among a presumed high-risk population. ELISA, MERS-CoV spike pseudoparticle neutralisation tests (ppNT) and plaque neutralisation tests (PRNT) were used to assess MERS-CoV seropositivity. Results: Serum samples were collected from camel slaughterhouse workers (n = 137), camel herders (n = 156) and individuals of the general population without occupational contact with camels but living in camel herding areas (n = 186). MERS-CoV neutralising antibodies with ≥ 90% reduction of plaque numbers were detected in two (1.5%) slaughterhouse workers, none of the camel herders and one individual from the general population (0.5%). Conclusions: This study provides evidence of zoonotic transmission of MERS-CoV in Morocco in people who have direct or indirect exposure to dromedary camels.


  • Open Access

    Genetics of breast cancer in African populations: a literature review

    by A. Abbad, H. Baba, H. Dehbi, M. Elmessaoudi-Idrissi, Z. Elyazghi, O. Abidi, F. Radouani

    Breast cancer (BC) is one of the most complex, diverse and leading cause of death in women worldwide. The present investigation aims to explore genes panel associated with BC in different African regions, and compare them to those studied worldwide.We extracted relevant information from 43 studies performed in Africa using the following criteria: case-control study, association between genetic variations and BC risk. Data were provided on mutations and polymorphisms associated with BC without fixing a specific date. Case-only studies and clinical trials were excluded.Our study revealed that the majority of African BC genetic studies remain restricted to the investigation of BRCA1 and BRCA2 genes and differences in their mutations spectrum. Therefore, it is necessary to encourage African researchers to characterize more genes involved in BC using methods generating global information such as next-generation sequencing in order to guide specific and more effective therapeutic strategies for the African community.